deltatrials

HIV infections Trials in Hampton, United States

Conditions / HIV infections / Hampton, United States

HIV infections has been the subject of sustained clinical investigation across multiple research sites.

51 total trials for this combination

Showing top 10 of 51 trials

Trials

NCT ID Title Status Phase
NCT00098722 Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects COMPLETED PHASE2/PHASE3
NCT00000979 Comparison of ddI Versus Zidovudine in HIV-Infected Patients COMPLETED PHASE2
NCT00000671 A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment COMPLETED PHASE2
NCT00245739 TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. APPROVED_FOR_MARKETING
NCT00002359 A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega COMPLETED PHASE3
NCT00365612 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients COMPLETED PHASE4
NCT00232908 QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection COMPLETED PHASE4
NCT00038532 Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART COMPLETED PHASE2
NCT00426660 Expanded Access Program for Maraviroc At Multiple Centers COMPLETED PHASE3
NCT00002124 A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3 COMPLETED PHASE3

Related Pages